List view / Grid view
A preliminary analysis shows VXA-CoV2-1 was well-tolerated and induced T-cell…
A preliminary analysis shows VXA-CoV2-1 was well-tolerated and induced T-cell and IgA responses against SARS-CoV-2 antigens in 35 patients.
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate,…
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.
Vaxart's application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine…
Vaxart's application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate has been cleared by the FDA.
The researchers suggest inducing a mucosal immune response may be…
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
